Skip to content

US · TLX · BIOTECHNOLOGY

Telix Pharmaceuticals Limited (TLX) intrinsic value and stock valuation

$8.37as of 2026-11-21 · Mkt cap 3.9B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Telix Pharmaceuticals Limited DCF and intrinsic value

InvestorsCraft values TLX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TLX’s statements →

Telix Pharmaceuticals Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology North Melbourne, VIC 3051 telixpharma.com

How the business is doing

Fiscal 1999–2025, USD

Revenue
$1.21B+197.1% 5y CAGRd
19992025
Net income
-$-10.69M
19992025
Free cash flow
-$-82.8M
20152025
Total equity
$622.3M+51.1% 5y CAGRd
20002025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 1999–2025, USD
20252024202320222021
Revenue$1.21B$783.2M$502.6M$160.1M$7.6M
Operating income$26.6M$82.1M$15.8M-$-91.93M-$-81.25M
Net income-$-10.69M$49.9M$5.21M-$-104.08M-$-80.51M
EPSd-$-31.64K$144.6K$16.1K-$-335.05K-$-285.28K
Operating cash flow-$-25.93M$43M$23.9M-$-63.97M-$-59.33M
Capital expenditure-$-56.86M-$-14.32M-$-9.68M-$-7.04M-$-1.34M
Free cash flow-$-82.8M$28.7M$14.2M-$-71.01M-$-60.67M
Total assets$1.77B$1.52B$398.3M$255.4M$109.8M
Total debt$699.8M$581.5M$17.5M$10.5M$2.54M
Net debt$487.2M-$-128.9M-$-105.79M-$-105.88M-$-19.5M
Total equity$622.3M$568.2M$148.9M$80M$2.16M
Cash and short-term investments$212.5M$710.4M$123.2M$116.3M$22M
Income statement
20252024202320222021
Revenue$1.21B$783.2M$502.6M$160.1M$7.6M
Cost of revenue$565.2M$273.5M$188.2M$65.2M$38.7M
Gross profit$640.2M$509.7M$314.4M$94.9M$5.05M
Research and development expenses$256.8M$121M$128.8M$57.9M$34.1M
Selling, general and administrative expenses$356.8M$207.1M$134.2M$87.1M$47M
Other expenses$0.00$99.4M$270K$41.9M-$-27.82M
Operating expenses$613.6M$427.6M$263.3M$186.9M$53.3M
Cost and expenses$1.18B$701.1M$486.7M$252M$92M
Interest income$8.74M$10.9M$670K$0.00$0.00
Interest expense$55.1M$21.5M$8.94M$410K$200K
Depreciation and amortization$32.7M$5.69M$6.74M$5.38M$5.17M
Ebitda$79.8M$98.2M$23M-$-92.84M-$-70.07M
Operating income$26.6M$82.1M$15.8M-$-91.93M-$-81.25M
Total other income/expenses, net-$-34.54M-$-26.07M-$-12.75M-$-6.69M-$-17.79M
Income before tax-$-7.9M$56.1M$3.09M-$-98.62M-$-99.04M
Income tax expense$2.79M$6.14M-$-2.07M$5.46M-$-18.53M
Net income-$-10.69M$49.9M$5.21M-$-104.08M-$-80.51M
Weighted average shares outstanding$337.9M$331.2M$319.2M$310.6M$282.2M
Weighted average diluted shares outstanding$337.9M$345.2M$323.7M$310.6M$282.2M
Balance sheet
20252024202320222021
Cash and short-term investments$212.5M$710.4M$123.2M$116.3M$22M
Net receivables$207.3M$159M$79.5M$31.1M$20.8M
Inventory$55.6M$38.1M$17.3M$5.77M$3.45M
Total current assets$494.8M$918.6M$224.9M$173.2M$47.5M
Property, plant and equipment, net$173.2M$54.3M$30.5M$18.8M$6.33M
Goodwill and intangible assets$888.1M$416.1M$109.7M$64.5M$59.8M
Long-term investments$55.6M$6.09M$12.3M-$-5.52M$0.00
Total non-current assets$1.28B$597.9M$173.5M$87.4M$62.3M
Total assets$1.77B$1.52B$398.3M$255.4M$109.8M
Accounts payable$107.4M$68.7M$32.8M$16.8M$11.9M
Short-term debt$28M$21.5M$1.56M$1.28M$630K
Deferred revenue$17.2M$11.3M$11M$4.94M$6.14M
Total current liabilities$347M$330.9M$157.4M$85.6M$38M
Long-term debt$671.8M$560M$15.9M$9.8M$1.91M
Deferred revenue, non-current$0.00$3.29M$12.2M$22.5M$23.1M
Total non-current liabilities$801.6M$617.3M$92M$89.8M$68.2M
Capital lease obligations$93M$10.6M$8.27M$7.13M$2.52M
Total liabilities$1.15B$948.2M$249.4M$175.4M$106.2M
Common stock$719M$596.8M$446.3M$371M$170.8M
Retained earnings-$-231.51M-$-212.96M-$-263.67M-$-272.81M-$-173.47M
Accumulated other comprehensive income (loss)$134.8M$184.4M-$-33.69M-$-18.15M$4.79M
Total equity$622.3M$568.2M$148.9M$80M$2.16M
Total investments$55.6M$6.09M$12.3M-$-5.52M$0.00
Total debt$699.8M$581.5M$17.5M$10.5M$2.54M
Net debt$487.2M-$-128.9M-$-105.79M-$-105.88M-$-19.5M
Cash flow statement
20252024202320222021
Net income-$-10.69M$49.9M$5.21M-$-104.08M-$-80.51M
Depreciation and amortization$32.7M$8.02M$6.74M$5.38M$5.17M
Stock-based compensation$0.00$19.7M$8.79M$8.11M$1.32M
Change in working capital-$-67.81M-$-98.82M-$-57.53M-$-28.64M-$-7.42M
Accounts receivable-$-30.69M-$-57.08M-$-27.38M-$-19.93M-$-7.19M
Inventory-$-11.46M-$-3.24M-$-9.64M-$-5.02M-$-2.82M
Accounts payable$43.5M$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-25.93M$43M$23.9M-$-63.97M-$-59.33M
Investments in property, plant and equipment-$-83.98M-$-14.32M-$-9.68M-$-7.04M-$-1.34M
Acquisitions, net-$-330.92M-$-34.69M-$-1.48M-$-970K$0.00
Net cash used for investing activities-$-428.79M-$-135.17M-$-25.49M-$-17M-$-2.73M
Common stock issued$2.71M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-5.58M$638.9M$10.2M$175M$2.85M
Net change in cash-$-446.35M$587.1M$6.91M$94.3M-$-55.91M
Cash at end of period$212.5M$710.4M$123.2M$116.3M$22M
Operating cash flow-$-25.93M$43M$23.9M-$-63.97M-$-59.33M
Capital expenditure-$-56.86M-$-14.32M-$-9.68M-$-7.04M-$-1.34M
Free cash flow-$-82.8M$28.7M$14.2M-$-71.01M-$-60.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Telix Pharmaceuticals Limited

        Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

        CEO
        Christian Behrenbruch
        Employees
        1.15K
        Beta
        0.63

        Explore

        Frequently asked questions

        What is the intrinsic value of Telix Pharmaceuticals Limited (TLX)?

        Telix Pharmaceuticals Limited (TLX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TLX undervalued?

        TLX trades at a price of $8.37 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.